Business
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic cancer, and two for NT219 in the treatment of colorectal and head and neck cancers, at the 2025 American Association for Cancer Research Meeting (
About this update from Purple Biotech Ltd.
[{"type":"image","alt":"Purple Biotech Ltd.","displaySize":"","headline":null,"caption":"Purple Biotech Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":250,"url":"https://media.zenfs.com/en/globenewswire.com/729a756a7144cb9ef11f13ad1f1036a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/b_q3OJwHS.6FpUIZPiP7Sg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/729a756a7144cb9ef11f13ad1f1036a5","width":300,"height":250}},"lazy":false},{"type":"text","content":"REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic cancer, and two for NT219 in the treatment of colorectal and head and neck cancers, at the 2025 American Association for Cancer Research Meeting (2025 AACR), scheduled to take place from April 25th to April 30th in Chicago. Presentation details are below:","length":629,"tagName":"p"},{"type":"text","content":"Abstract Title: Final analysis of the randomized Phase 2 cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer & potential serum biomarkers","length":157,"tagName":"p"},{"type":"text","content":"Session Title: Liquid Biopsy: Circulating Nucleic Acids 4 / Predictive Biomarkers 1","length":83,"tagName":"p","attribs":{}},{"type":"text","content":"Session Date and Time: Wednesday, April 30, 9:00 a.m. - 12:00 p.m.","length":66,"tagName":"p","attribs":{}},{"type":"text","content":"Abstract Title: APC-loss as a potential biomarker for NT219 treatment in colorectal cancer (CRC)","length":96,"tagName":"p"},{"type":"text","content":"Session Title: Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes","length":104,"tagName":"p","attribs":{}},{"type":"text","content":"Session Date and Time: Sunday, April 27, 2:00 - 5:00 p.m.","length":57,"tagName":"p","attribs":{}},{"type":"text","content":"Abstract Title: NT219 overcomes immune evasion-resistant mechanisms in head and neck squamous cell carcinoma (HNSCC)","length":116,"tagName":"p"},{"type":"text","content":"Session Title: Novel Drug Resistance...